retatrutide type 2 diabetes phase 2 results 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Triple hormone receptor agonist retatrutide
Description
If this is the case, she adds that its extremely important to be in contact with the patients therapist and/or psychiatrist
Lancet 400 (10366), 18691881 (2022)
Start with a short online questionnaire and, if appropriate, a video or message-based visit with a licensed clinician
The recommendations, published in the medical journal JAMA, emphasize that these medications alone are not a solution to treating the global obesity epidemic
In the U.S., this can be done through the FDAs MedWatch program
